-
To ling pharmaceutical industry won the "Advanced collective in Hebei Province to fight the new crown pneumonia epidemic"
Time of Update: 2020-10-28
in Singapore, Thailand, Romania and other nearly 20 countries and regions, and at the same time in the Middle East, Africa, Latin America and other 30 countries to start registration work, Chinese medicine hard nuclear disease resistance, "Lianhua" at home
-
Agios leukemia drug Tibsovo has been approved in the United States for its cold adaptation in Europe.
Time of Update: 2020-10-28
the failure highlighted the risks involved in FDA Director Richard Pazdur's rapid completion of approvals. , however, is not a complete loss of the European market, and for now, Tibsovo's remaining opportunities in Europe lie with patients who
-
The New Coronary Inactivated Vaccine obtained positive medium-term safety data in Phase 3 clinical trials.
Time of Update: 2020-10-28
Retrieved October 20, 2020, from the Brazilian National Health Supervision Agency approved Beijing Kexing Zhongwei Biotechnology Co., Ltd. new crown inactivated vaccine Kelleford ™️ to carry out Phase III.
-
East China Pharmaceuticals has signed an exclusive clinical development and commercialization agreement with ImmunoGen.
Time of Update: 2020-10-28
of down payment, clinical and registration milestones, sales milestones and sales fees, of which: (1) a down payment of US$40 million shall be paid within 15 working days of the signing and entry into force of the agreement; (2) Clinical and registration
-
Baiyunshan clarified the media reports: the follow-up needs to carry out further related work on the product.
Time of Update: 2020-10-28
1, Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd. ("Baiyunshan and Huang Company") for the Company's 50% shareholding of the joint venture, not included in the scope of the company's merger, the Company's use of long-term equity
-
AstraZeneone's new adaptation application was reviewed by the FDA on a priority note.
Time of Update: 2020-10-28
resources: .1) Tagrisso granted Priority Review in the US for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer.
-
SMA's first oral medicine! Roche Evrysdi's application for listing in Japan has been reviewed in China.
Time of Update: 2020-10-28
/> approved by Evrysdi, the FDA also issued Roche-owned Geneneck with a Rare Pediatric Disease Priority Review Certificate (PRV). as part of its ongoing commitment to SMA patients, Genentek has also submitted listing applications in Brazil, Chile
-
Data on the efficacy of 7 types of tumors were first published by Theoshi/Mershadon K drug combined with lenvatini.
Time of Update: 2020-10-28
with non-removable or advanced melanoma who had been treated with PD-1 or PD-L1 monoantigens, or who had progressed with other immuno-checkpoint inhibitors. during the study period, patients were given intravenously 200 mg of Pabliju monotherapy
-
52 drugs are out of supply nationwide.
Time of Update: 2020-10-28
injections and a sharp increase in prices. 2017 sales of calcium glucosate raw materials increased 19 times to 54.6 times compared to 2014 prices. earlier, Malay acid chlorobenamine rose 58 times in a month from 400 yuan/kg to 23,300 yuan/kg
-
Guaranteed approval? Consistency evaluation pile up, these varieties still have enterprise declaration!
Time of Update: 2020-10-28
such as Qilu only declared 3 items, namely, injection of acetic acid capofen net, methyl sulfate lunphatini capsules, hydrochloric acid Moxisa star eye drops.
-
Chengdu Bett took the "hepatitis B drug" the first imitation of 20 new products on the road.
Time of Update: 2020-10-28
to date, Chengdu Bett Pharmaceuticals in the review of the new classification of generic drugs reported 20 varieties (29 acceptance numbers), approved for production will be treated as a consistency evaluation.
-
Chengdu Bett took the "hepatitis B drug" the first imitation of 20 new products on the road.
Time of Update: 2020-10-28
to date, Chengdu Bett Pharmaceuticals has 20 varieties (29 acceptance numbers) of generic drugs reported in the new classification reviewed and will be treated as if they had passed a consistency evaluation after being approved for production.
-
Anhui Province to explore supplies two-vote system tax processing difficulty or increase.
Time of Update: 2020-10-28
-value medical supplies implementation program, emphasizing the need to strengthen circulation management. actively explore the province's public medical institutions through the "two-vote system" and other ways to reduce the circulation of high
-
Howson preempts Qilu! AstraZeneta's heavy sugar-lowering drug is under siege from domestic giants.
Time of Update: 2020-10-28
Figure 1: Registration of Shagritin tablets by Haussen Pharmaceuticals Source: NMPA Image caption AstraZeneta's global sales of Shagritin (in millions of dollars) Source: Miennet multinational listed company sales database Shagritin is II Peptidease
-
National drug sharing price data sheet is being developed, to be issued as soon as possible!
Time of Update: 2020-10-28
of medical security, will rely on the platform to achieve the whole process of service management functions such as networking, bidding, procurement, trading, settlement, payment and evaluation. , it will also play the functions of scientific
-
The Central Commission for Discipline Inspection informed: a number of pharmaceutical companies involved in pharmaceutical rebates.
Time of Update: 2020-10-28
the high amount of money involved, corruption interest chain link and so on, resulting in high prices of drugs and medical supplies, medical costs too fast growth, a large number of loss of medical insurance funds and other issues, increasing
-
The Central Commission for Discipline Inspection informed: a number of pharmaceutical companies involved in pharmaceutical rebates.
Time of Update: 2020-10-28
supplies rebate problem appears the most frequently, showing the high amount of money involved, corruption interest chain link and so on, resulting in high prices of drugs and medical supplies, medical costs too fast growth, a large number of loss
-
Emergency! The National Health Service has released a catalogue of recent developments.
Time of Update: 2020-10-28
-evident. E drug managers deliberately combed through some of the points and questions about this year's health-care catalog adjustment, and looked forward to readers participating in the discussion at the end of the article and asking more
-
Shandong will be Chinese medicine formula particles into health insurance! The scope of application is extended to primary medical institutions.
Time of Update: 2020-10-28
trial period, Shandong Province approved the research pilot enterprise production into the medical insurance payment of Chinese medicine formula particles applicable to the scope of application to the first level (including the first level) or more medical institutions.
-
Ano Pharmaceuticals was awarded the "2020 China China Health Industry Innovation Award - Best Biopharmaceutical Innovation Enterprise"
Time of Update: 2020-10-28
The list of "Best Biopharmaceutical Innovation Enterprises" was released by the Edo think tank, which explores the core strength of the medical innovation process by taking the innovation of enterprise projects, product differentiation, performance
